Uckan D, Cetin M, Yigitkanli I, Tezcan I, Tuncer M, Karasimav D, Oguz K K, Topçu M
Department of Pediatrics, Units of Bone Marrow Transplantation and Hematology, Hacettepe University Faculty of Medicine, Children's Hospital, Yenisehir, Ankara 06100, Turkey.
Bone Marrow Transplant. 2005 Jan;35(1):71-6. doi: 10.1038/sj.bmt.1704749.
Neurological complications may occur in BMT recipients (11-59%), frequently contributing to morbidity or mortality. They are the main causes of death in 10-15%. Life-threatening neurological complications were seen in 11 out of 113 (9.7%) children who underwent BMT from HLA-matched family (n=7) or mismatched donors (n=4) at our institution. Diagnoses of patients with neurological complications were acute myeloblastic leukemia (AML) (five), thalassemia major (two), Fanconi anemia (two), Omenn syndrome (one) and leukodystrophy (one), and the neurological events were seen between days +13 and +85 after transplantation. Minor symptoms including reversible, nonrepetitive seizures were excluded. Cyclosporine A toxicity was diagnosed in six children. The rest of the complications were brain abscess/meningoencephalitis (two), severe hypomagnesemia (one), busulfan toxicity (one), sustained hypertension (three), and intracranial hemorrhage (three). Six patients with neurological complications suffered from >grade II graft-versus-host disease (GvHD), and all were high risk for transplant-related complications. In this study, risk status of the underlying disease, mismatched transplantation, a diagnosis of AML (advanced stage), older age and >grade II GvHD were important adverse factors for the development of severe life-threatening neurological complications.
神经并发症可能发生在骨髓移植受者中(11%-59%),常导致发病或死亡。它们是10%-15%患者的主要死因。在我们机构接受来自HLA匹配的家族供者(n=7)或不匹配供者(n=4)骨髓移植的113名儿童中,有11名(9.7%)出现了危及生命的神经并发症。出现神经并发症的患者诊断为急性髓细胞白血病(AML)(5例)、重型地中海贫血(2例)、范可尼贫血(2例)、奥门综合征(1例)和脑白质营养不良(1例),神经事件发生在移植后第13天至第85天之间。排除了包括可逆性、非重复性癫痫发作在内的轻微症状。6名儿童被诊断为环孢素A毒性。其余并发症为脑脓肿/脑膜脑炎(2例)、严重低镁血症(1例)、白消安毒性(1例)、持续性高血压(3例)和颅内出血(3例)。6名出现神经并发症的患者患有>II级移植物抗宿主病(GvHD),且均有发生移植相关并发症的高风险。在本研究中,基础疾病的风险状态、不匹配移植、AML诊断(晚期)、年龄较大和>II级GvHD是发生严重危及生命的神经并发症的重要不利因素。